Amsterdam: A new class of cholesterol pills has cleared its most important European hurdle. On 24 July the European Medicines Agency’s scientific committee recommended approving two treatments built around obicetrapib, a drug designed to cut the harmful LDL cholesterol that hardens arteries and drives heart attacks and strokes.
The committee, known as the CHMP, backed marketing authorisation for Ubeslo, a once-daily tablet taken alone, and Evlarco, which combines obicetrapib with the established medicine ezetimibe in a single pill. NewAmsterdam Pharma developed the compound and the Menarini Group will help bring it to patients across Europe. A positive opinion from the committee almost always leads the European Commission to grant formal approval within roughly two months.
The need is large. Cardiovascular disease remains the leading cause of death in the European Union, and doctors have long relied on statins to push cholesterol down. Yet many patients cannot tolerate high statin doses or fail to reach their targets even on them, which leaves a stubborn group at high risk and hungry for new options.
Obicetrapib offers one. The drug blocks a protein called CETP, and in trials it lowered LDL cholesterol sharply when added to standard care. Its appeal lies partly in its form, a pill swallowed once a day, unlike some of the newest cholesterol therapies that patients must inject. Convenience often decides whether people stick with a lifelong treatment, and a simple tablet tends to win that contest.
The recommendation caps a busy stretch for the agency. Earlier in July its safety committee reviewed contraceptives containing desogestrel and etonogestrel and updated the guidance doctors give women about rare risks. Regulators also fast-tracked a medicine for an aggressive pancreatic cancer, a sign of how the agency juggles routine safety work with the push to speed promising therapies to people who have few alternatives.
Cost and access come next. National health systems, not the agency, decide which medicines they will pay for, and a fresh cholesterol drug will face hard questions about price and value once it reaches the market. Payers will weigh it against cheap generic statins and ask how much extra benefit the new pill delivers for the money.
For now the science has spoken in the drug’s favour. If the Commission follows the committee, as it usually does, European doctors will soon hold another tool against a disease that still kills more Europeans than any other, and millions of patients who struggle with cholesterol may gain a simpler way to bring it under control.
